title: Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
abstract: OBJECTIVE
  All-trans retinoic acid combined to anthracycline-based chemotherapy is the standard regimen of acute promyelocytic leukemia. The advent of arsenic trioxide has contributed to improve the anti-leukemic efficacy in acute promyelocytic leukemia. The objectives of the current study were to evaluate if dual induction by all-trans retinoic acid and arsenic trioxide could accelerate the recovery of abnormality of coagulation and fibrinolysis in patients with acute promyelocytic leukemia.
  
  
  METHODS
  Retrospective analysis was performed in 103 newly-diagnosed patients with acute promyelocytic leukemia. Hemostatic variables and the consumption of component blood were comparably analyzed among patients treated by different induction regimen with or without arsenic trioxide.
  
  
  RESULTS
  Compared to patients with other subtypes of de novo acute myeloid leukemia, patients with acute promyelocytic leukemia had lower platelet counts and fibrinogen levels, significantly prolonged prothrombin time and elevated D-dimers (P<0.001). Acute promyelocytic leukemia patients with high or intermediate risk prognostic stratification presented lower initial fibrinogen level than that of low-risk group (P<0.05). After induction treatment, abnormal coagulation and fibrinolysis of patients with acute promyelocytic leukemia was significantly improved before day 10. The recovery of abnormal hemostatic variables (platelet, prothrombin time, fibrinogen and D-dimer) was not significantly accelerated after adding arsenic trioxide in induction regimens; and the consumption of transfused component blood (platelet and plasma) did not dramatically change either. Acute promyelocytic leukemia patients with high or intermediate risk prognostic stratification had higher platelet transfusion demands than that of low-risk group (P<0.05).
  
  
  CONCLUSIONS
  Unexpectedly, adding arsenic trioxide could not accelerate the recovery of abnormality of coagulation and fibrinolysis in acute promyelocytic leukemia patients who received all-trans retinoic acid combining chemotherapy.
authors.affiliation: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: Ye
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: SiJing
authors.initials: S
authors.lastname: Wu
authors.affiliation: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: Dan
authors.initials: D
authors.lastname: Luo
authors.affiliation: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: JianFeng
authors.initials: J
authors.lastname: Zhou
authors.affiliation: Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
authors.forename: DengJu
authors.initials: D
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology* / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010087:Oxides / Q000494:pharmacology* / Q000627:therapeutic use; D010976:Platelet Count; D011517:Prothrombin Time; D012189:Retrospective Studies; D014212:Tretinoin / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001152:Arsenicals; D005338:Fibrin Fibrinogen Degradation Products; D010087:Oxides; C036309:fibrin fragment D; D014212:Tretinoin; D005340:Fibrinogen; D000077237:Arsenic Trioxide
references.citation: Semin Thromb Hemost. 2014 Apr;40(3):332-6
references.pmid: 24590422
references.citation: N Engl J Med. 2013 Jul 11;369(2):111-21
references.pmid: 23841729
references.citation: Best Pract Res Clin Haematol. 2014 Mar;27(1):33-8
references.pmid: 24907015
references.citation: Blood. 1999 Nov 15;94(10):3315-24
references.pmid: 10552940
references.citation: Blood. 2001 Jan 1;97(1):264-9
references.pmid: 11133770
references.citation: Blood. 2002 Dec 15;100(13):4298-302
references.pmid: 12393590
references.citation: Eur J Haematol. 2003 Jul;71(1):1-8
references.pmid: 12801292
references.citation: Best Pract Res Clin Haematol. 2003 Sep;16(3):463-82
references.pmid: 12935963
references.citation: Blood. 2004 Feb 15;103(4):1237-43
references.pmid: 14576047
references.citation: Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
references.pmid: 15044693
references.citation: Cancer. 1981 Jan 1;47(1):207-14
references.pmid: 7459811
references.citation: Blood. 1992 Feb 1;79(3):543-53
references.pmid: 1732003
references.citation: Br J Haematol. 2012 Jan;156(1):24-36
references.pmid: 22050876
references.citation: Leukemia. 2012 Mar;26(3):433-42
references.pmid: 21904379
references.citation: Blood. 2012 Aug 23;120(8):1570-80; quiz 1752
references.pmid: 22715121
references.citation: J Clin Oncol. 1992 Sep;10(9):1413-8
references.pmid: 1517784
references.citation: Leukemia. 1993 Jan;7(1):2-9
references.pmid: 8418375
references.citation: Leukemia. 1995 Sep;9(9):1461-6
references.pmid: 7658712
references.citation: Br J Haematol. 1996 Mar;92(3):733-9
references.pmid: 8616045
references.citation: Blood. 1996 Oct 15;88(8):2826-32
references.pmid: 8874178
references.citation: Thromb Res. 2005;116(2):109-14
references.pmid: 15907524
references.citation: Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8
references.pmid: 15894607
references.citation: Blood. 2006 May 1;107(9):3469-73
references.pmid: 16373661
references.citation: Cancer. 2007 Apr 1;109(7):1355-9
references.pmid: 17326049
references.citation: Blood. 2007 Jul 1;110(1):59-66
references.pmid: 17374742
references.citation: Blood. 2008 Mar 1;111(5):2505-15
references.pmid: 18299451
references.citation: Blood. 2008 Apr 1;111(7):3395-402
references.pmid: 18195095
references.citation: Nat Cell Biol. 2008 May;10(5):547-55
references.pmid: 18408733
references.citation: Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
references.pmid: 19225113
references.citation: Best Pract Res Clin Haematol. 2009 Mar;22(1):153-63
references.pmid: 19285282
references.citation: Blood. 2009 Jul 30;114(5):937-51
references.pmid: 19357394
references.citation: Blood. 2010 Nov 11;116(19):3751-7
references.pmid: 20705755
references.citation: Leukemia. 2011 Jul;25(7):1128-34
references.pmid: 21502956
references.citation: Lancet. 2012 Oct 13;380(9850):1309-16
references.pmid: 22877506
references.citation: Hematology Am Soc Hematol Educ Program. 2012;2012:157-60
references.pmid: 23233575
references.citation: Best Pract Res Clin Haematol. 2014 Mar;27(1):11-8
references.pmid: 24907013